Themis Medicare Limited
THEMISMED · NSE · Healthcare
With a 20% margin of safety, our buy-below price is ₹156.63. Low-confidence estimate — limited data.
Piotroski F-score 1/9 — quality of earnings & balance sheet.
Investability checklist
- ✕ROE above 15%0.3%
- ✓Low debt (D/E < 0.5)0.25x
- ✕Positive free cash flow
- ✕Revenue growth > 10%7%
- –Earnings growing
- ✕Net margin ≥ 10%0.3%
- ✓Current ratio > 1.51.83
- ✓Below our fair value
- ✓Margin of safety ≥ 20%
- ✓Above 200-day average
- ✓Above 50-day average
- –Positive 1-year return
- ✓Altman Z in safe zoneZ 4.13
- ✕Piotroski ≥ 71/9
1-year price
EOD · 2026-06-16Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Quarterly results
Annual financials
Shareholding
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
SWOT snapshot
Strengths
- •Lightly leveraged balance sheet.
- •Financially solid — Altman Z 4.13.
Weaknesses
- •Low return on equity (0.3%).
- •Weak Piotroski score (1/9).
Opportunities
- •Trades ~93% below our estimated fair value.
About Themis Medicare Limited
Themis Medicare Limited, together with its subsidiaries, manufactures and sells pharmaceutical products in India and internationally. It offers active pharmaceutical ingredients (APIs) and formulations used in various therapeutic areas, including anti-tuberculosis, analgesic and anti-inflammatory, analgesic and antispasmodic, analgesics, anesthesia, antacid-antiflatulent, anti-fungal, antibiotic, anti-diabetic, anti-emetic, anti-hypertensive, anti-allergic and anti-inflammato
More in Healthcare
Our verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.